tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Opthea Faces Leadership Changes Amidst Clinical Trial Setbacks

Story Highlights
Opthea Faces Leadership Changes Amidst Clinical Trial Setbacks

Elevate Your Investing Strategy:

Opthea ( (AU:OPT) ) has shared an announcement.

Opthea Limited announced the resignation of four directors following the failure of its Phase 3 trials to meet primary endpoints and a significant workforce reduction. The company is in negotiations with Development Funding Agreement investors to explore future options, amidst trading suspensions on ASX and Nasdaq due to financial uncertainties.

The most recent analyst rating on (AU:OPT) stock is a Buy with a A$1.25 price target. To see the full list of analyst forecasts on Opthea stock, see the AU:OPT Stock Forecast page.

More about Opthea

Opthea Limited operates in the biotechnology industry, focusing on the development of therapies for treating eye diseases. The company is primarily engaged in advancing ophthalmology science through clinical trials and drug development.

YTD Price Performance: -25.93%

Average Trading Volume: 6,651,653

Technical Sentiment Signal: Sell

Current Market Cap: A$738.8M

Learn more about OPT stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1